KEYNOTE-667 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

1,188 results for “KEYNOTE-667”

Trials

View all 507 →

Active, not recruiting

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

340 participants · First posted Jan 23, 2018

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

590 participants · First posted Jan 31, 2017

A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema

2 participants · First posted Dec 4, 2020

Drugs

View all 300 →

MK-6592

Palovarotene

Conditions: Heterotopic Ossification (HO)

C₂₇H₃₀N₂O₂

Icatibant(Firazyr, Sajazir, Icatibant Accord)

Conditions: ACE Inhibitor-associated Angioedema, Hereditary angioedema breakthrough attack

C₅₉H₈₉N₁₉O₁₃S · Rx

Organizations

The University of Alabama

United States

Cholayil Pvt Ltd.

India

NATIONAL UNIVERSITY OF SINGAPORE

Singapore

News

View all 375 →

CAR T-Cell Therapy Shows Improved Survival in Transformed Follicular Lymphoma

Pembrolizumab Shows Promise in Younger Patients with Low-Risk Hodgkin Lymphoma

Merck Highlights Hematology Pipeline at ASH 2024 with Zilovertamab Vedotin and Nemtabrutinib Data

Page 1 of 119